Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); Donidalorsen for patients with hereditary angioedema; and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 that has completed Phase 2 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals Inc. ($IONS) announced an update on their ongoing clinical study. The study titled A Phase 2, Open-label Trial Evaluating the...

Ionis Advances ION775 Phase 2 Trial in High Triglycerides: What Investors Should Watch

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Teva Pharmaceutical (TEVA), Ionis Pharmaceuticals (I...

Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Ionis Pharmaceuticals (IONS) and Rhythm Pharmaceuticals (RYTM)

In a report released yesterday, Yaron Werber from TD Cowen reiterated a Buy rating on Ionis Pharmaceuticals, with a price target of $108.00. Werber...

TD Cowen Remains a Buy on Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals ( ($IONS) ) has provided an update. On June 12, 2026, Ionis Pharmaceuticals reported positive new data from its CORE-OLE open...

Ionis Highlights Positive Long-Term Olezarsen Data in Hypertriglyceridemia

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Madrigal Pharmaceuticals (MDGL), Moderna (MRNA) an...

Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Moderna (MRNA) and Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals ( ($IONS) ) just unveiled an update. Ionis Pharmaceuticals on June 4, 2026, appointed veteran biopharmaceutical executive Lud...

Ionis Pharmaceuticals Adds Veteran Leader to Board

The latest announcement is out from Ionis Pharmaceuticals ( ($IONS) ). On May 28, 2026, Ionis Pharmaceuticals said partner GSK reported positive pi...

Ionis Gains on Positive Phase 3 Hepatitis B Data

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ClearPoint Neuro (CLPT) and Ionis Pharmaceuticals (I...

Analysts Are Bullish on Top Healthcare Stocks: ClearPoint Neuro (CLPT), Ionis Pharmaceuticals (IONS)

The biotech sector has always held a special appeal for risk-tolerant investors. While these companies face high overhead in the form of towering R...

Market Cap	$10.76B	P/E Ratio	N/A
52W High	$86.74	52W Low	$36.93
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-7.8%	52W Position	74.7%
Overall Score	47	Value Score	40
Quality Score	52	Technical Score	50

EPS Current Est	$-3.64	EPS Next Est	$-1.77
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IONS	$74.12	-0.26%	2.98M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IONS	$74.12	-0.3%	2.98M
3
4
5
6

IONS

IONS

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Ionis Pharmaceuticals Inc. Data in Excel

Get Ionis Pharmaceuticals Inc. Data in Excel